WEST LAFAYETTE, Ind., July 26, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced the appointment of David Meek to the newly created position of chief commercial officer. Mr. Meek will be responsible for the development of Endocyte’s commercial team and the Company’s overall commercial strategy and execution.
